This is read by an automated voice. Please report any issues or inconsistencies here. Evangeline Lilly says much of her brain is “functioning at a decreased capacity” after her traumatic brain injury ...

Evangeline Lilly revealed on social media that she has brain damage after suffering a concussion last year when she fell into a boulder. The “Lost” and “Ant-Man” star said that “almost every area in ...

The 'Lost' and 'Ant Man' star revealed in a health update the “bad news about my concussion” including “decreased brain capacity” after a May 2025 holiday mishap in Hawaii. By Etan Vlessing Canada ...

Evangeline Lilly says she has brain damage, months after fainting and hitting her head on a rock while at the beach. “It’s late on January 1st. The first day of 2026. And I’m entering into this new ...

Evangeline Lilly is sharing an update on her health following an unfortunate accident in May 2025. In an Instagram video posted on Friday, Jan. 2, the 46-year-old "Lost" star shared that she has ...

India's obesity drug market expected to exceed $1 billion in two years, analyst says Lilly's Mounjaro leads in sales, Novo cuts prices to compete Lilly and Novo partner with local firms to expand ...

View post: Lululemon sends stern warning to customers about its leggings View post: Stock Market Today, Jan 27: Tech lifts S&P 500 to fresh record as TikTok outage, Trump Medicare surprise weigh in ...

Eli Lilly's next-gen anti-obesity candidate hit it out of the park in a phase 3 study. This should help solidify the company's lead in this niche of the industry. Even after their strong run, Lilly's ...

Eli Lilly’s weight loss drugs have delivered blockbuster sales in recent quarters. The company is a leader in this market today and has a pipeline of promising candidates to potentially reinforce its ...

A next-generation obesity shot from Eli Lilly & Co. helped patients lose almost a quarter of their body weight, potentially making the experimental drug the most potent weight-loss medicine yet. The ...

Eli Lilly has surpassed analysts’ highest hopes for the efficacy of retatrutide, linking the triple agonist to 28.7% weight loss and a 75.8% reduction in pain scores in patients with obesity and knee ...

This hasn’t been a great market for so-called quality stocks, typically defined as blue chips with steady profits and low debt. That makes it all the more impressive that funds run by GMO’s Tom ...